Reporting Noncompliance in Clinical Labs Requires the Right Channels and Culture
A lawyer advises medical laboratories on how to improve their avenues for reporting unethical behavior
Compliance-lca
Subscribe today for access to
Articles and Reports
Next Steps: With LDT Final Rule Now Null, Industry Groups Urge Lab Managers and Pathologists to Advocate for Change
CAP and AMP officials weigh in on plans to push for a legislative- or CLIA-based approach to future LDT oversight
Further Details to Note about Updated Clinical Lab Director Qualifications
Put into place late last year, the new rules place more emphasis on formal and continuing education requirements
Already a member? Log in here
Changes in hazardous waste management: the Generator Improvement Rule
By Dan Scungio, MT (ASCP), SLS, CQA (ASQ) bio
If you haven't heard by now, you should know that the EPA published its Generator Improvement Rule (GIR) in 2016. It is an update to the…
Surviving a Medicare Audit: Warn Lab Staffers Not to Lie to Auditors
From - Lab Compliance Advisor
As a lab compliance director, you understand the dangers of obstructing a Medicare audit. The problem is…
Compliance Alert: New Private-Pay Opioid Law Puts All Drug Addiction & Rehab Labs at Risk of Federal Prosecution
From - Lab Compliance Advisor
Recent federal legislation addressing the opioid crisis may have unintended consequences on the lab industry. The idea was to allow the feds to prosecute a certain kind of…
Carreyrou Captivates Lab Institute With Inside Look at Theranos Fall
From - G2 Compliance Advisor
The tale could be headed to movie theaters around the nation soon. It is a gripping story of a Steve Jobs–wannabe—a young Stanford dropout with…
The Safety Interpretation
By Dan Scungio, MT (ASCP), SLS, CQA (ASQ) bio
When hospitals were placed on OSHA's list of "high-risk" workplaces, no one had to ask why. OSHA adjusts that list based on the number of injuries that occur on the job…
OIG Work Plan Monthly Review: July 2018
From - G2 Compliance Advisor
None of the six new items that OIG added to its Work Plan last month directly impact labs…
How PAMA’s Effect in 2018 Molecular Diagnostic Reimbursement Will Make Labs More Money
By Sean McSweeney bio
The year 2018 is slated to be much brighter for molecular diagnostic labs as PAMA fee schedules show a higher payment rate and amount for many cancer genomics and…
Compliance Perspectives: The 12 Things to Include in Your Drug & Alcohol Testing Policy
From - G2 Compliance Advisor
No! No! No! The truth is that state laws on marijuana use and possession have little to no direct impact on workplace drug policies and the testing methods used…
OIG Work Plan Monthly Review: May 2018
From - G2 Compliance Advisor
Of the seven new Work Plan items, none directly impact labs and lab services. However, one item on Medicare Part B reimbursement of outpatient cardiac and…